Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allylamine SCHEMBL6144765 | 0.78 | — | — | |
| Allylamine SCHEMBL15197 | 0.78 | — | — | |
| Allylamine SCHEMBL6032547 | 0.78 | — | — | |
| Allylamine SCHEMBL11351826 | 0.74 | — | — | |
| Cyclohexane SCHEMBL2246753 | 0.74 | ALDH1A1 (0.75) | ALDH1A1 | |
| Cyclohexane SCHEMBL9284958 | 0.74 | ALDH1A1 (0.75) | ALDH1A1 | |
| Allylamine SCHEMBL169953 | 0.73 | — | — | |
| Allylamine SCHEMBL13256599 | 0.73 | — | — | |
| Allylamine SCHEMBL5891273 | 0.73 | — | — | |
| Allylamine SCHEMBL3369484 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112111260-B | Displacement leading edge outburst locking agent system and preparation method thereof | 西南石油大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-112111260-A | Displacement leading edge outburst locking agent system and preparation method thereof | 西南石油大学 | 2020-12-22 | — | — | CN | disclosed |
| US-9938332-B2 | Modified ghrelin peptides | Kanagawa, Kenji (JP) | 2018-04-10 | — | — | US | disclosed |
| US-9573986-B2 | Modified ghrelin peptides | KENJI KANGAWA (JP) | 2017-02-21 | — | — | US | disclosed |
| US-8524871-B2 | Modified gherlin peptides | Kangawa, Kenji (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20130172251-A1 | MODIFIED GHRELIN PEPTIDES | KANGAWA KENJI (JP) | 2013-07-04 | — | — | US | disclosed |
| EP-2119785-B1 | Novel peptides | KANGAWA KENJI (JP) | 2013-03-13 | — | — | EP | disclosed |
| US-8227570-B2 | Modified gherlin peptides | Kanagawa, Kenji (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20110184153-A1 | MODIFIED GHERLIN PEPTIDES | KANGAWA KENJI | 2011-07-28 | — | — | US | disclosed |
| US-20100240866-A1 | MODIFIED GHERLIN PEPTIDES | KANGAWA KENJI | 2010-09-23 | — | — | US | disclosed |
| EP-1795598-B1 | Novel peptides | KANGAWA KENJI (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119785-A1 | Novel peptides | Kangawa, Kenji (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090170763-A1 | Modified gherlin peptides | KANGAWA KENJI | 2009-07-02 | — | — | US | disclosed |
| US-7385026-B1 | Modified ghrelin polypeptides | Kangawa, Kenji (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1197496-B1 | NOVEL PEPTIDES | KANGAWA KENJI (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1795598-A1 | Novel peptides | Kangawa, Kenji (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-1197496-A1 | NOVEL PEPTIDES | Kangawa, Kenji (JP) | 2002-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184153-A1 | MODIFIED GHERLIN PEPTIDES | GHSR, GHRHR, GHITM | ALDH1A1 4867/4885GRIN2D 1219/4885GRIN3B 326/4885 |
| US-20090170763-A1 | Modified gherlin peptides | GHSR, GHRHR, GHITM | ALDH1A1 4867/4885GRIN2D 1219/4885GRIN3B 326/4885 |
| US-20130172251-A1 | MODIFIED GHRELIN PEPTIDES | GHSR, GIPR, GHRHR | ALDH1A1 4811/4885GRIN2D 931/4885GRIN3B 250/4885 |
| US-20100240866-A1 | MODIFIED GHERLIN PEPTIDES | GHSR, GHRHR, GHITM | ALDH1A1 4867/4885GRIN2D 1219/4885GRIN3B 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.